AN2 Therapeutics Inc (ANTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has a cash flow conversion efficiency ratio of -0.092x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.00 Million) by net assets ($75.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANTX stock market capitalisation for the company's overall valuation and market capitalisation.
AN2 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AN2 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AN2 Therapeutics Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of AN2 Therapeutics Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
T-Robotics.Co.Ltd
KQ:117730
|
-0.078x |
|
Talisker Resources Ltd
TO:TSK
|
-0.381x |
|
Lithium Royalty Corp
TO:LIRC
|
-0.001x |
|
Cymechs Inc
KQ:160980
|
0.045x |
|
SPACSphere Acquisition Corp. Class A Ordinary Shares
NASDAQ:SSAC
|
0.000x |
|
Service & Quality Technology Co Ltd
TWO:3219
|
-0.014x |
|
Kencana Energi Lestari
JK:KEEN
|
-0.006x |
|
Expensify Inc
NASDAQ:EXFY
|
0.063x |
Annual Cash Flow Conversion Efficiency for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of AN2 Therapeutics Inc from 2019 to 2025. View AN2 Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.06 Million | $-29.83 Million | -0.562x | +6.57% |
| 2024-12-31 | $81.85 Million | $-49.26 Million | -0.602x | -40.83% |
| 2023-12-31 | $124.70 Million | $-53.29 Million | -0.427x | -21.79% |
| 2022-12-31 | $95.37 Million | $-33.46 Million | -0.351x | -6.04% |
| 2021-12-31 | $61.91 Million | $-20.48 Million | -0.331x | +83.03% |
| 2020-12-31 | $2.75 Million | $-5.36 Million | -1.950x | -277.50% |
| 2019-12-31 | $4.81 Million | $-2.49 Million | -0.517x | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more